ArticleFrontiers in medicine2026

Metabolomics reveals LysoPC a C17:0 (LPC 17:0) as candidate biomarker for personalized medicine in morbid obesity.

Eleonora Stefanini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.